Article Text

Download PDFPDF
New details emerge about the implementation of the Falsified Medicines Directive's safety features and verification requirements
  1. Richard Price
  1. Correspondence to Richard Price, Department of Policy and Advocacy, European Association of Hospital Pharmacy, 3 Rue Abbe Cuypers, Brussels 1040, Belgium; richard.price{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

All hospital pharmacies in Europe will be under a legal obligation to implement new medicines verification requirements in 2018. The new requirements come as a result of the 2011 Falsified Medicines Directive. Further details of what this is likely to mean in practice for hospital pharmacists have recently been emerging.

The European Association of Hospital Pharmacy (EAHP) and its members remain seriously concerned about the implications and burden such obligations will place on hospital pharmacy, which across Europe already operates in resource-restrained environments.

The 2011 Directive gives only headline attention to what the pan-European verification system for medicines might consist of: a verification system based on unique identifiers linked to a repository. All of the details relating to the technical specifications, modalities and management of the new verification system are instead left to the European Commission to propose via a second set of regulations called a ‘Delegated …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.